| Document |
Document Title |
|
WO/2024/033917A1 |
Provided herein is a composition comprising solid particles or granules comprising Phosphorylcholine-tuftsin conjugate including a salt thereof, and ester end-capped poly(glycolide-co-lactide), wherein the Phosphorylcholine- tuftsin conj...
|
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
|
WO/2024/031949A1 |
A preparation method for nano-enzyme composite hydrogel eye drops. A coordination reaction of cobalt chloride hexahydrate and ammonia water and an oxidation-reduction reaction of silver nitrate and tannic acid are utilized to synthesize ...
|
|
WO/2024/032584A1 |
The present invention relates to a protein tyrosine kinase inhibitor for treating protein tyrosine kinase-mediated proliferative diseases or symptoms, such as ocular diseases and malignant tumors accompanied by pathological neoangiogenes...
|
|
WO/2024/034610A1 |
This frozen and thawed hydrogel comprises a modified polyvinyl alcohol, and a drug. This method for producing a frozen and thawed hydrogel comprises: executing, at least twice, a freezing and thawing cycle in which a composition containi...
|
|
WO/2024/028483A1 |
The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.
|
|
WO/2024/028495A1 |
The present invention relates generally to substituted ergoline compounds and compositions, more particularly new lysergamide derivatives and compositions, and applications of these. The invention furthermore relates to a new production ...
|
|
WO/2024/028487A1 |
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said NGF is administered intranasally to said subject.
|
|
WO/2024/028519A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, Y and A are as defined herein. These compounds are photodynamic agents that generates reactive oxygen species when subjected to UV radiation. The invention also...
|
|
WO/2024/029597A1 |
Provided is a dry eye remedy that can selectively inhibit IFN-γ, has no risk of biological contamination, and can be stored at room temperature. Provided is a dry eye remedy containing, as an active ingredient, a DNA oligonucleotide tha...
|
|
WO/2024/028558A1 |
The subject of the present invention is that of preparing glucosylated mycosporines by means of an enzymatic cascade method using α-transglucosylases and sucrose, and use thereof in particular for their anti-UV properties.
|
|
WO/2024/027451A1 |
Provided are an oil-in-water cyclosporin emulsion and a method for preparing same. The oil-in-water cyclosporin emulsion comprises an interface stabilizer comprising a combination of polyethylene glycol (15)-hydroxystearate and phospholi...
|
|
WO/2024/027116A1 |
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...
|
|
WO/2024/030000A1 |
The present invention provides a compound as a HIF-1α inhibitor or an inhibitor against VEGF as an angiogenesis inducer and a pharmaceutical composition for the prevention or treatment of HIF-1α- or VEGF-related diseases, comprising sa...
|
|
WO/2024/029599A1 |
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methox
yphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolid
ine-3-yl]-5-(trifluoromethyl)phenyl}p...
|
|
WO/2024/023239A1 |
The present invention relates to a combination of nerve growth factor and sesamin, and uses thereof in the treatment of ophthalmic disorders.
|
|
WO/2024/023535A1 |
The present teaching relates to peptides that are capable of regulating the trafficking of leukocytes. This has applications in the treatment and/or prophylaxis of conditions associated with leukocyte migration, including inflammatory di...
|
|
WO/2024/022173A1 |
Provided in the present application are the use of andrographolide, or a pharmaceutically acceptable salt thereof, or a solvate thereof in the preparation of a drug for treating hearing impairment, and the use of a pharmaceutical composi...
|
|
WO/2024/026478A1 |
The present disclosure features compositions and methods for editing a 290-KD centrosomal protein (CEP290) gene to treat a congenital eye disorder, such as Leber's Congenital Amaurosis-10. In embodiments, the disclosure provides methods ...
|
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
|
WO/2024/025817A1 |
Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrid
o[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use t...
|
|
WO/2024/024920A1 |
The present invention provides a novel ophthalmic composition. The ophthalmic composition comprises polysulfated chondroitin sulfate as an active ingredient thereof. This composition is effective for preventing and/or treating keratoconj...
|
|
WO/2024/025497A1 |
The invention relates to a chemical neutralisation eyewash that forms a layer on the eye, allowing it to reach the daily pH level of 7.4 between 1 and 20 seconds, preventing damage to the eye upon a chemical splash to prevent the burning...
|
|
WO/2024/021429A1 |
The present invention belongs to the field of biotechnology, and particularly relates to a gene delivery system targeting retina and use thereof. The gene delivery system targeting retina comprises an adeno-associated virus vector rAAV11...
|
|
WO/2024/024395A1 |
Provided is a pharmaceutical or food and beverage composition which is for prevention or treatment of an optic nerve disorder and which includes diosgenin or a diosgenin derivative as an active ingredient thereof.
|
|
WO/2024/026273A1 |
A method of treating and/or reducing ototoxicity caused by a chemotherapeutic agent in a mammalian subject, comprising administering to the subject a therapeutically effective amount of a chemotherapeutic agent, and administering to the ...
|
|
WO/2024/022778A1 |
The present invention relates to a combination product comprising, as active substances, at least vitamin A, B1, B2, B3, B5, B6, B8, B9, B12, C, D, E, selenium, zinc, molybdenum, iron, manganese, magnesium, calcium, copper, lutein, Siber...
|
|
WO/2024/019171A1 |
The purpose of the present invention is to provide a composition that improves conditions related to ocular blood flow by evaluating effects on ocular blood flow. Provided is a composition for improving and/or maintaining ocular blood fl...
|
|
WO/2024/018090A1 |
The present invention relates to a preservative-free ophthalmic composition comprising a carbonic anhydrase inhibitor for use in the reduction of elevated intraocular pressure during a treatment period of at least 90 days. The compositio...
|
|
WO/2024/020475A1 |
The present disclosure provides photocurable hydrogel compositions and methods of using in the treatment of tympanic membrane perforations.
|
|
WO/2024/017315A1 |
The present invention provides use of a steroid compound in the preparation of a medicament for preventing and/or treating myopia. The steroid compound provided in the present invention is represented by formula (I), has the effects of t...
|
|
WO/2024/018073A1 |
The present invention provides derivatives of quinolylnitrones of formula I, wherein the meaning of the substituents is as described in the description, useful in treatment and/or prevention of hearing loss. Advantageously, these quinoly...
|
|
WO/2024/017844A1 |
The present invention refers to the new use of a glucagon-like peptide (GLP-1) agonist for treating loss of smell.
|
|
WO/2024/016640A1 |
The present invention relates to an antihistamine compound, and a preparation method therefor and the use thereof. Specifically, the present invention relates to an antihistamine compound having a structure of formula I and a pharmaceuti...
|
|
WO/2024/018469A1 |
The present disclosure relates to combination the combination, pharmaceutical compositions and kits comprising at least two small molecule inhibitors (SMIs) of respectively at least two proteins of different signaling pathways of retinal...
|
|
WO/2024/017845A1 |
The invention relates to a product suitable for the treatment of tear film deficiency in dry eye disease and a method for manufacturing the product. The invention also relates to a product for use in the treatment of tear film deficiency...
|
|
WO/2024/014851A1 |
The present invention provides a purine derivative compound as a HIF-1 protein inhibitor or an inhibitor against VEGF as an angiogenesis inducer, and a pharmaceutical composition for the prevention or treatment of related diseases, compr...
|
|
WO/2024/015705A1 |
Provided herein is an AAV2 vector encoding SEQ ID NO: 4 as the optogenetic protein, and methods of use for e.g., retinitis pigmentosa.
|
|
WO/2024/013565A1 |
Implants comprising steroid dimers for use in improving vision and treating ocular disorders and conditions are provided. Said steroid dimers have the structure D1-L-D2 with D1 and D2 preferably being dexamethasone with the dexamethasone...
|
|
WO/2024/015594A1 |
Provided herein are irradiated mouse models which recapitulate the effects of ionizing radiation-induced microglia activation, eye injury and retinal degeneration, as well as methods for producing such mouse models. These mouse models ar...
|
|
WO/2024/012425A1 |
The present invention relates to a compound, a pharmaceutical composition containing same, a preparation method therefor, and the use thereof as an RIPK1 inhibitor. The compound is a compound as represented by formula (I), or an optical ...
|
|
WO/2024/014792A1 |
The present invention relates to a pharmaceutical composition and a food composition, for the prevention or treatment of degenerative retinal diseases, corneal epithelium wounds, and dry eye syndrome, comprising retinal organoid-derived ...
|
|
WO/2024/011449A1 |
Disclosed is a use of retinal pigment epithelial cells in replacement of corneal endothelial cells, and prevention and treatment of diseases or symptoms such as corneal endothelial function decompensation. The retinal pigment epithelial ...
|
|
WO/2024/015595A1 |
This disclosure relates to compositions for improving ear health and treating conditions associated with a subject's ear. In particular, the disclosure relates to compositions formulated as a wipe comprising an antiseptic agent, an antif...
|
|
WO/2024/011817A1 |
The present invention belongs to the field of biomedicine, and relates to a recombinant adeno-associated virus loaded with a c-Rel-specific ribonucleic acid and the use thereof in inhibiting corneal transplant rejection. The recombinant ...
|
|
WO/2024/015791A1 |
Described herein are antibodies that bind VEGF_A or ANG-2, or bispecific antibodies that bind VEGF_A and ANG-2. Antibodies of this disclosure are useful for treating diseases of the eye including macular degeneration.
|
|
WO/2024/008114A1 |
The present invention relates to an siRNA capable of inhibiting the expression of a complement factor B (CFB) gene, an siRNA conjugate, a pharmaceutical composition comprising same, and a use thereof. Each nucleotide in the siRNA is inde...
|
|
WO/2024/010765A1 |
Aspects of the invention are drawn to compositions and methods of treating a 5-HT2-mediated condition in a subject in need thereof. In embodiments, the 5-HT2-mediated condition is a 5-HT2A-mediated ocular condition. In some embodiments, ...
|
|
WO/2024/010044A1 |
The present invention relates to an ophthalmic composition containing tramadol or a salt thereof, wherein the ophthalmic composition is accommodated in a container of which part or all of a portion coming into contact with the ophthalmic...
|
|
WO/2024/008844A1 |
The present invention relates to a process for preparing hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hept
en-1-yl]- 3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester Compound (I). I...
|
